Standardizing Treatments for Pulmonary Exacerbations: A platform for evaluating treatment decisions to improve outcomes (STOP360)

CFF treatment guidelines for the management of pulmonary exacerbations (PEx) identified evidence gaps in current clinical best practices. The STOP program offers a platform for the conduct of controlled trials to develop the evidence base in order to define clinical best practices. The study is a prospective, multicenter, parallel group study. Participants will be in a study for up to 48 days ((+ or -) 2 days): The interventional Aminoglycoside Study (AG Study) will be a randomized (1:1 ratio), open-label, superiority study of intravenous aminoglycoside and [BETA]-lactams versus intravenous [BETA]-lactams only. Randomization will occur at Visit 1